Last reviewed · How we verify

Liposomal Bupivacaine with Bupivacaine

Jamaica Hospital Medical Center · Phase 3 active Small molecule

Liposomal Bupivacaine with Bupivacaine is a Local anesthetic Small molecule drug developed by Jamaica Hospital Medical Center. It is currently in Phase 3 development for Local anesthesia for surgical procedures, Infiltration anesthesia and nerve blocks. Also known as: Exparel.

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, with the liposomal formulation providing prolonged drug release and extended anesthesia duration.

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, with the liposomal formulation providing prolonged drug release and extended anesthesia duration. Used for Local anesthesia for surgical procedures, Infiltration anesthesia and nerve blocks.

At a glance

Generic nameLiposomal Bupivacaine with Bupivacaine
Also known asExparel
SponsorJamaica Hospital Medical Center
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhasePhase 3

Mechanism of action

Bupivacaine works by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, preventing depolarization and blocking nerve conduction. The liposomal encapsulation allows for sustained release of the active drug, extending the duration of local anesthetic effect compared to conventional bupivacaine formulations. This combination formulation may provide both immediate anesthesia (from free bupivacaine) and prolonged anesthesia (from the liposomal component).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Liposomal Bupivacaine with Bupivacaine

What is Liposomal Bupivacaine with Bupivacaine?

Liposomal Bupivacaine with Bupivacaine is a Local anesthetic drug developed by Jamaica Hospital Medical Center, indicated for Local anesthesia for surgical procedures, Infiltration anesthesia and nerve blocks.

How does Liposomal Bupivacaine with Bupivacaine work?

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, with the liposomal formulation providing prolonged drug release and extended anesthesia duration.

What is Liposomal Bupivacaine with Bupivacaine used for?

Liposomal Bupivacaine with Bupivacaine is indicated for Local anesthesia for surgical procedures, Infiltration anesthesia and nerve blocks.

Who makes Liposomal Bupivacaine with Bupivacaine?

Liposomal Bupivacaine with Bupivacaine is developed by Jamaica Hospital Medical Center (see full Jamaica Hospital Medical Center pipeline at /company/jamaica-hospital-medical-center).

Is Liposomal Bupivacaine with Bupivacaine also known as anything else?

Liposomal Bupivacaine with Bupivacaine is also known as Exparel.

What drug class is Liposomal Bupivacaine with Bupivacaine in?

Liposomal Bupivacaine with Bupivacaine belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Liposomal Bupivacaine with Bupivacaine in?

Liposomal Bupivacaine with Bupivacaine is in Phase 3.

What are the side effects of Liposomal Bupivacaine with Bupivacaine?

Common side effects of Liposomal Bupivacaine with Bupivacaine include Injection site reactions, Transient neurological symptoms, Hypotension, Bradycardia, Systemic toxicity (at high doses).

What does Liposomal Bupivacaine with Bupivacaine target?

Liposomal Bupivacaine with Bupivacaine targets Voltage-gated sodium channels and is a Local anesthetic.

Related